RNA BIOCHEMISTRY IS ONE OF THE MOST PROMISING AREAS OF MEDICINAL INNOVATION

First Health Pharmaceuticals has a leading position in the field of advanced RNA biochemistry. We aim to further develop our portfolio of highly active patented RNA Helicase inhibiting lead compounds and bring revolutionary pharmaceuticals to the market that will offer new hope for patients suffering from some of the most challenging diseases of our time.

HIV

First Health Pharmaceuticals developed the first ever generation of Translation Inhibitor antiretroviral compounds effective against HAART resistant HIV strains

TLR ACTIVATOR

First Health Pharma has been investigating potential Wakeup strategies to be applied in a HIV Shock & Kill approach since early 2016 when we started studying the potential use of Interleukins and Toll-like Receptor (TLR) activators

BREAST CANCER

The role of DDX3 in breast cancer has been studied most extensively. Our DDX3 Inhibitors were successfully tested on metastatic breast cancer cell lines expressing DDX3

COMPUTER-AIDED DRUG DESIGN

Through the use of proprietary software, statistical analysis tools and machine learning algorithms, First Health Pharmaceuticals brought computer aided drug development to a new level

LOW ATTRITION RATE

First Health Pharma prioritizes the development of compounds with optimal physico-chemical profile, from the early phases of drug discovery pipeline, to increase the chances of research project success.

 

DENGUE

No antivirus was thus far available against Dengue virus, but our anti Dengue lead compound demonstrates excellent antiviral activity combined with very low cytotoxicity